| Literature DB >> 22808213 |
Yi Sun1, Shuang Yu, Peng Sun, Haiyan Wu, Weidong Zhu, Wei Liu, Jue Zhang, Jing Fang, Ruoyu Li.
Abstract
We investigated the antifungal effect of non-thermal plasma, as well as its combination with common antifungal drugs, against Candida biofilms. A direct current atmospheric pressure He/O(2) (2%) plasma microjet (PMJ) was used to treat Candida biofilms in a 96-well plate. Inactivation efficacies of the biofilms were evaluated by XTT assay and counting colony forming units (CFUs). Morphological properties of the biofilms were evaluated by Scanning Electron Microscope (SEM). The sessile minimal inhibitory concentrations (SMICs) of fluconazole, amphotericin B, and caspofungin for the biofilms were also tested. Electron Spin Resonance (ESR) spectroscopy was used to detect the reactive oxygen species (ROS) generated directly and indirectly by PMJ. The Candida biofilms were completely inactivated after 1 min PMJ treatment, where severely deformed fungal elements were observed in SEM images. The SMICs of the tested antifungal drugs for the plasma-treated biofilms were decreased by 2-6 folds of dilution, compared to those of the untreated controls. ROS such as hydroxyl radical ((•)OH), superoxide anion radical ((•)O(2) (-)) and singlet molecular oxygen ((1)O(2)) were detected by ESR. We hence conclude that He/O(2) (2%) plasma alone, as well as in combination with common antifungal drugs, is able to inactivate Candida biofilms rapidly. The generation of ROS is believed to be one of the underlying mechanisms for the fungicidal activity of plasma.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22808213 PMCID: PMC3393702 DOI: 10.1371/journal.pone.0040629
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Evaluation of the inactivation rates of Candida biofilms treated with PMJ by CFU count (1-1a, 1-2a, 1-3a) and XTT assay (1-1b, 1-2b, 1-3b).
Figure 2SEM results of C. albicans SC5314 biofilm before and after plasma treatment, the magnification scale were ×5000 and ×22000: (a), a negative control treated with He/O2 flow; (b), treated with PMJ for 10 s; (c), treated with PMJ for 20 s; (d), treated with PMJ for 30 s; (e), treated with PMJ for 60 s.
Figure 3(a) The signal of DMPO-OH; (b) The influence of mannitol on the DMPO-OH signal; (c) The influence of SOD on the DMPO-OH signal.
Figure 4(a) The signal of TEMPO; (b) 1O2 existence verified by L-His
.
The SMIC50, 80 (µg/ml) and MIC (µg/ml) of FLC, AMB and CAP.
| Isolate | Source | Species | Untreated(MIC) | Untreated (SMIC50/80) | 10 s(SMIC50/80) | 20 s(SMIC50/80) | 30 s(SMIC50/80) | ||||||||||
| FLC | AMB | CAP | FLC | AMB | CAP | FLC | AMB | CAP | FLC | AMB | CAP | FLC | AMB | CAP | |||
| BMU02971 | Pharynx |
| ≥64 | 2 | 1 | ≥256 | 0.5/4 | 1/2 | ≤1/8 | ≤0.125/0.5 | ≤0.015/0.5 | ≤1 | ≤0.125 | ≤0.015 | ≤1 | ≤0.125 | ≤0.015 |
| BMU03213 | Oral mucosa |
| 1 | 0.5 | 0.5 | ≥256 | 0.25/0.5 | 0.25/0.5 | ≤1/4 | ≤0.125/0.25 | ≤0.015/0.5 | ≤1 | ≤0.125 | ≤0.015 | ≤1 | ≤0.125 | ≤0.015 |
| BMU04801 | Oral mucosa |
| 2 | 2 | 0.5 | ≥256 | 1/4 | 0.5/1 | 8/32 | 0.25/0.25 | 0.06/0.5 | ≤1 | ≤0.125 | ≤0.015 | ≤1 | ≤0.125 | ≤0.015 |
| SC5314 | Blood |
| 2 | 1 | 0.5 | ≥256 | 1/2 | 0.25/0.5 | 16/64 | 0.25/0.5 | 0.06/0.25 | ≤1 | ≤0.125 | ≤0.015 | ≤1 | ≤0.125 | ≤0.015 |
| BMU00279 | Sputum |
| ≥64 | 1 | 1 | ≥256 | 1/1 | 1/1 | ≤1/4 | ≤0.125/0.25 | ≤0.015/0.5 | ≤1 | ≤0.125 | ≤0.015 | ≤1 | ≤0.125 | ≤0.015 |
| BMU05102 | Oral mucosa |
| ≥64 | 1 | 0. 5 | ≥256 | 0.5/1 | 0.25/0.5 | ≤1/8 | ≤0.125/0.25 | ≤0.015/0.25 | ≤1 | ≤0.125 | ≤0.015 | ≤1 | ≤0.125 | ≤0.015 |
| BMU05137 | Oral mucosa |
| ≥64 | 1 | 2 | ≥256 | 2/4 | 0.5/1 | 2/16 | ≤0.125/0.25 | ≤0.015/0.03 | ≤1 | ≤0.125 | ≤0.015 | ≤1 | ≤0.125 | ≤0.015 |
| BMU00271 | Blood |
| ≥64 | 1 | 0.5 | ≥256 | 0.5/1 | 0.25/0.5 | ≤1/4 | ≤0.125/0.25 | ≤0.015/0.25 | ≤1 | ≤0.125 | ≤0.015 | ≤1 | ≤0.125 | ≤0.015 |
| BMU01689 | Knee |
| 32 | 2 | 1 | ≥256 | 0.5/2 | 0.25/1 | 2/8 | ≤0.125/0.25 | ≤0.015/0.25 | ≤1 | ≤0.125 | ≤0.015 | ≤1 | ≤0.125 | ≤0.015 |
| BMU04388 | Intraperitoneal fluid |
| 32 | 1 | 0.5 | ≥256 | 0.5/1 | 1/2 | 2/4 | ≤0.125/0.5 | 0.5/1 | ≤1 | ≤0.125 | ≤0.015 | ≤1 | ≤0.125 | ≤0.015 |
MIC, minimal inhibitory concentration, used for evaluating the antifungal activity of antifungal drugs against planktonic cell of Candida species; SMIC, sessile minimum inhibitory concentration, used for evaluating the antifungal activity of antifungal drugs against Candida biofilms.
SMIC50 values were equal to SMIC80 values.